Investor interest in biopharma company Amarin (NASDAQ: AMRN) mounted this summer as the company gained approval from the Food and Drug Administration for its triglyceride-lowering drug, Vascepa. In an effort to help investors examine both the bull and bear cases for this stock, we've put together a brand new premium research report on Amarin that examines the company's market opportunity, biggest threats, and reasons to both buy and sell today.

In the following video, Austin Smith talks with health care analyst Max Macaluso about why this drug has garnered so much attention, what Vascepa actually does, and the competition that Amarin could soon face once this new medication reaches patients.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.